PeptideJournal
Guides13 min read

Peptides for Dental & Oral Health Research

Your mouth already runs on peptides. Saliva contains dozens of antimicrobial peptides — small proteins that kill bacteria, fight fungi, and help repair damaged tissue.

Your mouth already runs on peptides. Saliva contains dozens of antimicrobial peptides — small proteins that kill bacteria, fight fungi, and help repair damaged tissue. LL-37, defensins, and the copper-binding tripeptide GHK-Cu are all present in oral fluids, working around the clock to keep infection in check.

Researchers are now asking: what if we could use those same peptides — along with synthetic ones — to treat cavities, gum disease, implant infections, and enamel loss?

The answer is still unfolding. But the body of preclinical evidence is growing fast, with studies now spanning periodontitis, dental caries, enamel remineralization, implant coatings, and post-surgical healing. Here is what the science says so far.

Table of Contents

Why Peptides Matter for Oral Health

The oral cavity is one of the most microbiologically active environments in the human body — home to over 700 bacterial species, constantly exposed to mechanical stress from chewing, and bathed in a fluid (saliva) that must balance antimicrobial defense with tissue repair [1].

Traditional antibiotics work by targeting specific metabolic pathways in bacteria. Peptides take a different approach. Most antimicrobial peptides physically disrupt microbial cell membranes — a mechanism that makes resistance much harder to develop [2]. Beyond killing bacteria, many of these peptides also reduce inflammation, recruit immune cells, and stimulate tissue regeneration.

That triple function — antimicrobial, anti-inflammatory, and regenerative — is why dental researchers are paying close attention. A single peptide could, in theory, fight infection at a surgical site while simultaneously speeding healing. That is a hard combination for conventional drugs to match.

Antimicrobial Peptides Already in Your Mouth

Over 45 antimicrobial peptides (AMPs) have been identified in human saliva and gingival crevicular fluid (the fluid that seeps between your teeth and gums). Two families dominate [3]:

LL-37 (Cathelicidin)

LL-37 is the only cathelicidin in the human body. It is a 37-amino-acid peptide released by epithelial cells and immune cells in the gums, tongue, and salivary glands. Its amphipathic helix anchors into microbial membranes and tears them apart.

What makes LL-37 interesting for dentistry goes beyond germ-killing:

  • Periodontitis biomarker. Patients with gum disease show elevated LL-37 in their gingival crevicular fluid. Researchers have proposed using salivary LL-37 levels as a diagnostic marker for periodontitis severity [4].
  • Dentin regeneration. LL-37 stimulates odontoblastic cells to form reparative dentin and increases expression of dentin sialophosphoprotein (DSPP), suggesting it could function as a pulp-capping agent [5].
  • Anti-cancer activity. In oral squamous cell carcinoma models, LL-37 induces cancer cell death through membrane disruption and apoptotic pathways [2].

Human Beta-Defensins (HBD-1, 2, 3)

Defensins are expressed throughout the oral cavity — in gingival epithelium, buccal tissue, dental pulp, and salivary glands. HBD-1 is constitutively expressed at low levels, while HBD-2 and HBD-3 ramp up in response to bacterial colonization and inflammation [6].

In vitro studies show broad-spectrum activity against Streptococcus mutans (the primary cavity-causing bacterium), Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, and Candida albicans [7]. Genetic variation in the DEFB1 gene encoding HBD-1 has been linked to caries susceptibility — one meta-analysis found that individuals with a specific polymorphism (rs11362 TT genotype) had roughly seven times higher risk of dental caries compared to those with the CC genotype [8].

BPC-157 and Periodontal Disease

BPC-157 is a 15-amino-acid peptide derived from human gastric juice. It has been studied for wound healing and anti-inflammatory effects across multiple organ systems. In dentistry, the most relevant study comes from Semmelweis University in Budapest.

Researchers induced periodontitis in rats using a 12-day ligature model. The ligature caused significant gum inflammation, plasma leakage in gingival tissue, and alveolar bone destruction — the same bone loss that characterizes advanced gum disease in humans [9].

BPC-157 treatment produced three measurable effects:

  1. Reduced plasma extravasation — less fluid leakage from inflamed gingival blood vessels
  2. Lower histological inflammation scores — less tissue damage under the microscope
  3. Decreased alveolar bone resorption — the bone around the teeth was better preserved

Importantly, BPC-157 did not alter blood circulation in healthy gingiva — it only affected inflamed tissue. Acute toxicology testing showed no toxic or lethal effects even at very high doses (2 g/kg) [9].

A separate study examined BPC-157's antinociceptive (pain-reducing) properties in an incisional pain model. The peptide showed short-term pain reduction in the initial phase after incision, though the effect did not persist into later phases [10]. For post-surgical dental pain, this could have practical value — but longer-duration pain relief would need additional strategies.

For more on peptides that address inflammation, see our guide on the best peptides for inflammation.

TB-500 and Gingival Tissue Repair

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid peptide found in nearly every human tissue. Its primary biological function is sequestering G-actin, which maintains a pool of building-block proteins that cells can rapidly deploy for migration and repair.

Gingival Fibroblast Protection

A study published in the European Journal of Oral Sciences tested thymosin beta-4 directly on human gingival fibroblasts — the cells responsible for maintaining connective tissue in your gums. The peptide showed cytoprotective effects, shielding these cells from damage [11].

Periodontal Ligament Effects

A 2016 study found that thymosin beta-4 suppressed osteoclastic differentiation (the process that breaks down bone) and reduced inflammatory responses in human periodontal ligament cells [12]. Osteoclast overactivity is a key driver of the bone loss seen in periodontitis.

Wound Healing Relevance

In general wound models, thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days compared to controls. It also boosted collagen deposition and new blood vessel formation [13]. For the oral cavity — where post-extraction sockets, surgical incisions, and tissue grafts all need fast closure — this re-epithelialization speed matters. Faster surface healing means less infection risk and shorter time before procedures like implant placement.

TB-500 also reduces the number of myofibroblasts in wounds, which leads to less scar tissue formation [13]. In periodontal surgery, where scar tissue can interfere with tissue regeneration, this property is particularly relevant. Learn more about peptide combinations for tissue repair in our peptide stacking guide.

GHK-Cu: Collagen, Bone, and Oral Wound Healing

GHK-Cu is a naturally occurring tripeptide found in human plasma, saliva, and urine. Plasma levels decline with age — from about 200 ng/mL at age 20 to around 80 ng/mL by age 60 — which correlates with decreased regenerative capacity [14].

GHK-Cu is relevant to oral health for several reasons:

  • Collagen synthesis and remodeling. It stimulates both the production and organized breakdown of collagen and glycosaminoglycans, modulating the activity of matrix metalloproteinases (MMPs) and their inhibitors. This balanced remodeling is exactly what periodontal tissue repair requires [14].
  • Bone tissue repair. GHK-Cu has demonstrated ability to improve boney tissue healing in animal models — relevant for alveolar bone preservation after extraction or implant surgery [15].
  • Anti-inflammatory action. Copper complexes of GHK reduce TNF-alpha-induced secretion of IL-6 in fibroblasts, suggesting potential as a topical anti-inflammatory agent for oral mucosa [14].
  • Blood vessel and nerve regrowth. GHK stimulates angiogenesis and nerve outgrowth — both of which are needed for full recovery after oral surgery [15].

No studies have yet tested GHK-Cu specifically in dental clinical settings. But its presence in saliva and its documented effects on bone, collagen, inflammation, and wound healing make it a logical candidate for future oral health research. For background on GHK-Cu's role in wound repair, see our guide on best peptides for wound healing.

Self-Assembling Peptides for Enamel Regeneration

Enamel is the hardest substance in the human body — more than 95% mineral — but once it is damaged, it cannot regenerate on its own. Unlike bone or skin, there are no cells left to rebuild it after the tooth matures. That makes enamel caries a one-way street under current treatment: drill and fill.

Self-assembling peptides offer a different approach. These are short peptide sequences designed to spontaneously organize into scaffold-like structures that mimic the extracellular matrix of natural tooth tissue.

P11-4: From Lab to Clinical Trials

P11-4 is an 11-amino-acid peptide that exists as random coils in neutral solution but shifts to an antiparallel beta-sheet conformation at low pH — exactly the acidic conditions found at a cavity site. When it assembles, it forms a scaffold with negatively charged domains that attract calcium ions, triggering the growth of new hydroxyapatite crystals — the mineral that makes up natural enamel [16].

Clinical evidence shows:

  • P11-4 combined with fluoride produced remineralization superior to fluoride alone for early caries lesions [17]
  • The newly formed mineral layer integrates with underlying enamel at the molecular level, rather than sitting on top as a patch [16]
  • The peptide has been introduced into routine dental practice in some settings as a safe, noninvasive treatment for initial caries [18]

Amelogenin-Derived Peptides

Amelogenin is the protein that guides enamel formation during tooth development. Once the tooth matures, amelogenin is no longer produced. Researchers have created synthetic peptide fragments that replicate its mineralizing function:

  • P26 and P32 retain functional domains capable of regenerating enamel and dentin microstructures. P26 in a chitosan delivery system (P26-CS) was selected as a prototype for potential clinical use [19].
  • TRAP (Tyrosine-Rich Amelogenin Peptide) promoted remineralization of early enamel caries in situ — an important step beyond lab-only experiments [20].
  • QP5 stabilizes amorphous calcium phosphate and directs its transformation into hydroxyapatite crystals. Combined with fluoride, QP5 showed synergistic remineralization effects [21].

These peptide-based approaches represent a genuine paradigm shift: instead of patching damaged teeth with synthetic materials, they guide the tooth to rebuild itself using the same mineral it originally contained.

Peptide Coatings for Dental Implants

Dental implant failure often stems from bacterial colonization — specifically, the formation of biofilms on the implant surface that lead to peri-implantitis (infection and bone loss around the implant).

A December 2024 systematic review identified antimicrobial peptide coatings as the most studied and promising surface modification for controlling bacterial colonization on implants. These coatings outperformed both synthetic antimicrobial molecules and metallic nanoparticles in terms of potency, durability, and biocompatibility [22].

Peptide-based implant coatings work because they can be:

  • Covalently bonded to titanium surfaces for long-lasting protection
  • Designed for slow release to provide sustained antimicrobial activity
  • Engineered for selectivity to kill pathogens without harming surrounding host cells

Several AMPs — including derivatives of LL-37 and synthetic peptides like GH12 — have been tested as implant coatings in preclinical models. Clinical validation is still needed, but the preclinical results are encouraging.

Peptide Comparison Table

PeptidePrimary Oral ApplicationStage of ResearchKey Mechanism
LL-37Antimicrobial defense, periodontitis biomarkerClinical biomarker studiesMembrane disruption, immune modulation
DefensinsCaries prevention, oral homeostasisGenetic association studiesBroad-spectrum antimicrobial activity
BPC-157Periodontal inflammation, bone preservationAnimal studies (rats)Anti-inflammatory, angiogenic
TB-500Gingival tissue repair, post-surgical healingIn vitro + animal modelsActin regulation, cell migration
GHK-CuCollagen remodeling, bone repairPreclinical (no dental-specific trials)MMP modulation, angiogenesis
P11-4Enamel remineralizationClinical trialsSelf-assembly, hydroxyapatite nucleation
Amelogenin peptidesEnamel and dentin regenerationIn vitro + in situ studiesBiomimetic mineralization

Where the Research Stands

Most peptide applications in dental and oral health remain preclinical. Here is an honest snapshot:

Closest to clinical use:

  • P11-4 for enamel remineralization (already in limited clinical practice)
  • LL-37 as a diagnostic biomarker for periodontal disease
  • Antimicrobial peptide coatings for dental implants (systematic reviews support further development)

Promising but still in animal models:

  • BPC-157 for periodontitis (one well-designed rat study)
  • TB-500 for gingival tissue protection (in vitro and animal data)

Theoretical but well-supported:

  • GHK-Cu for oral wound healing (strong general evidence, no dental-specific trials)
  • Amelogenin-derived peptides for enamel regeneration (moving from lab to in situ)

No peptide discussed here has FDA approval for dental applications. BPC-157 and TB-500 are not approved for human clinical use by any regulatory authority. Self-assembling peptides like P11-4 are further along in the regulatory process, with clinical trial data supporting their use in enamel repair.

FAQ

Are peptides currently used in dental offices? Self-assembling peptide P11-4 (marketed under brand names like Curodont Repair) has been introduced in some dental practices for early caries treatment. Most other peptides discussed here remain research compounds.

Can BPC-157 help with gum disease? One animal study showed BPC-157 reduced gum inflammation and bone loss in rats with experimentally induced periodontitis. This is promising but far from clinical proof. No human trials have tested BPC-157 for periodontal disease.

Is LL-37 a treatment or just a biomarker? Both, potentially. LL-37 is already used as a research biomarker for periodontal disease severity. As a therapeutic, it has shown activity against oral pathogens and some ability to stimulate dentin repair, but clinical development for dental treatment is early-stage.

Can peptides actually regrow tooth enamel? In laboratory and in situ studies, amelogenin-derived peptides and P11-4 have produced new hydroxyapatite layers that integrate with natural enamel. This is not the same as regrowing a full tooth, but it represents a real advance over conventional filling and fluoride-only approaches for early-stage cavities.

Do antimicrobial peptides cause antibiotic resistance? Resistance development to AMPs is much slower than to conventional antibiotics because peptides work by physically disrupting cell membranes rather than targeting specific metabolic pathways. However, some bacterial resistance to natural AMPs has been documented, so this is an active area of monitoring [2].

What about peptide mouthwashes or toothpastes? Several peptide-containing oral care formulations are in development, including C16G2 for dental caries (in clinical trials), Nal-P-113 for periodontitis, and P-113 for oral candidiasis [2]. Commercial availability is limited, and most formulations remain experimental.

The Bottom Line

Your mouth is already a peptide-powered system. LL-37 and defensins patrol the gum line, GHK-Cu circulates in your saliva, and amelogenin built your enamel before you were born. What researchers are doing now is learning how to harness those same biological tools — and engineer new ones — to fight cavities, treat gum disease, protect implants, and even rebuild damaged enamel.

The science is not there yet for most applications. BPC-157's periodontitis data comes from a single rat study. TB-500's gingival effects are limited to cell culture and animal models. GHK-Cu has never been tested in a dental-specific clinical trial.

But self-assembling peptides for enamel repair are already in clinical practice. Antimicrobial peptide coatings for implants are in late preclinical development. And the pipeline of peptide-based oral therapeutics entering clinical trials — C16G2, Nal-P-113, P-113 — suggests that the gap between research and routine dental care is narrowing.

For readers interested in peptides that support tissue healing more broadly, our guides on best peptides for wound healing, best peptides for gut health, and best peptides for immune support cover adjacent research.

References

  1. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol. 2010;192(19):5002-5017. PubMed
  2. Li X, et al. Antimicrobial peptides in oral medicine: From mechanisms to clinical translation. Transl Dent Res. 2025. ScienceDirect
  3. Gorr SU. Antimicrobial peptides in periodontal innate defense. Front Oral Biol. 2012;15:84-98. PubMed
  4. Kemi B, et al. Cathelicidin LL-37 in periodontitis: current research advances and future prospects. Int Immunopharmacol. 2025. PubMed
  5. Zehnder M, et al. Cathelicidin LL-37 in health and diseases of the oral cavity. Biomedicines. 2022;10(5):1086. PMC
  6. Diamond G, Ryan L. Beta-defensins: what are they REALLY doing in the oral cavity? Oral Dis. 2011;17(7):628-635. PMC
  7. Joly S, et al. Human β-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol. 2004;42(3):1024-1029. PMC
  8. Lips A, et al. Association between rs11362 polymorphism in the beta-defensin 1 (DEFB1) gene and dental caries: A meta-analysis. Arch Oral Biol. 2021;121:104983. ScienceDirect
  9. Keremi B, Lohinai Z, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009;60(Suppl 7):143-145. PubMed
  10. Park JM, et al. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. J Dent Anesth Pain Med. 2022;22(2):97-105. PMC
  11. Reti R, Kwon E, Qiu P, et al. Thymosin β4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):431-437. PubMed
  12. Lee SI, Yi JK, Bae WJ, et al. Thymosin beta-4 suppresses osteoclastic differentiation and inflammatory responses in human periodontal ligament cells. PLoS ONE. 2016;11(1):e0146708. PubMed
  13. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed
  14. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Res Int. 2015;2015:648108. PMC
  15. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMC
  16. Jablonski-Momeni A, et al. Biomimetic enamel regeneration using self-assembling peptide P11-4. Biomimetics. 2023;8(3):290. PMC
  17. Doberdoli D, et al. Self-assembling peptide P11-4 and fluoride for regenerating enamel. J Dent Res. 2019;98(3):313-318. PMC
  18. Jablonski-Momeni A, et al. Effectiveness of self-assembling peptide (P11-4) in dental hard tissue conditions: A comprehensive review. Dent J. 2022;10(2):12. PMC
  19. Mukherjee K, Ruan Q, Moradian-Oldak J. Peptide-mediated biomimetic regrowth of human enamel in situ. ACS Omega. 2020;5(49):31532-31542. PMC
  20. Yang Y, et al. Effect of the recombinant amelogenin peptide TRAP on remineralization of early enamel caries: an in-situ study. BMC Oral Health. 2025;25:256. PMC
  21. Fan M, et al. Amelogenin-inspired peptide, calcium phosphate solution, fluoride and their synergistic effect on enamel biomimetic remineralization. Dent Mater. 2024;40(3):523-532. PMC
  22. Alshammari H, et al. Antibacterial coatings for dental implants: A systematic review. J Prosthodont Res. 2024. PubMed